Extremely positive news from Pfizer vaccine for coronavirus, which proved to be more effective than expected.
Specifically, according to the Wall Street Journal, the vaccine developed by Pfizer Inc. and BioNTech SE proved better than expected for protecting humans against coronavirus in Covid-19 in a central study.
This development is a milestone in the vaccine race that can stop the global pandemic. The vaccine proved to be more than 90% effective in the first 94 people infected with the new coronavirus and developed at least one symptom, the companies said on Monday.
And all this while pharmaceutical companies and research centers around the world are working feverishly for a safe and effective vaccine, in an effort to end the coronavirus pandemic that has claimed the lives of over 1,250,000 people worldwide. Scientists are hoping for a coronavirus vaccine that will be at least 75% effective, while prominent White House epidemiologist and consultant Dr. Anthony Fauci has said that a 50% to 60% effective vaccine would be acceptable. The Greek origin chairman and CEO of Pfizer, Albert Burle , hailed the development as a “great day for science and humanity.”
The results were based on the first interim efficacy analysis performed by an external and independent data monitoring committee from the Pfizer vaccine Phase 3 clinical trial. An independent panel of experts oversees US clinical trials to ensure the safety of participants.
The assay evaluated 94 confirmed Covid-19 infections among the 43,538 participants in the trial. Pfizer and BioNTech reported that analyzing the results in the two groups of people who took the test – those who received the vaccine and those who received placebo – showed an efficacy rate of more than 90% seven days after the second dose.
This means that protection against Covid-19 is achieved 28 days after the initial vaccination, which consists of a two-dose program. The final efficacy of the vaccine may vary, however, as safety and additional data continue to be collected.
“The first set of results from phase 3 clinical trials of the Covid-19 vaccine provides the initial demonstration of our vaccine’s ability to prevent COVID-19,” Burlas said in a statement. “We are reaching this critical milestone in the vaccine development program at a time when people need it more than ever as infection rates hit new heights, hospitals are on the verge of collapse and economies are struggling to reopen,” he said.
“With today’s news we are one step closer to providing people around the world with a much-needed discovery to help end this global health crisis. “We look forward to announcing additional vaccine efficacy and safety data from thousands of participants in the coming weeks.” About 42% of test participants had different backgrounds, Pfizer and BioNTech reported, adding that serious concerns about vaccine safety have not yet been reported. The companies said they plan to apply for authorization for emergency use permission from the US Food and Drug Administration as soon as they have two-month data, which is expected in the third week of November.
It should be noted, however, that the efficacy of the Pfizer vaccine in critical subgroups such as the elderly is not yet known, and whether the vaccine can prevent severe cases, as none of the participants who contracted Covid- 19 in this round of analysis.
Note that Pfizer and BioNTech expect to have 50 million doses of the vaccine this year and 1.3 billion by 2021.